Dr. Holtorf on Peptides: Cutting Through the Noise
Peptides have become one of the most talked-about and least understood topics in health optimization. Dr. Kent Holtorf, who has been working with peptide therapies in clinical practice for years, sits down to give a 101-level overview that covers the basics without dumbing it down. If you are hearing about peptides for the first time or feeling overwhelmed by conflicting information, this is a solid starting point.
A peptide is simply a chain of amino acids. Shorter than a protein, longer than a single amino acid. Your body makes thousands of them naturally, and they act as signaling molecules, telling cells what to do. Think of them as text messages between cells. Some tell your pituitary gland to release growth hormone. Others reduce inflammation. Others accelerate tissue repair. The synthetic versions used in therapy are designed to mimic or amplify these natural signals.
Dr. Holtorf emphasizes a point that gets lost in social media discussions: peptides are not steroids, not hormones, and not drugs in the traditional sense. They are signal amplifiers. The distinction matters because the risk profile is fundamentally different from exogenous hormone replacement. When you inject testosterone, you are adding hormone to your system and suppressing natural production. When you use a growth hormone releasing peptide, you are asking your pituitary to produce more of its own growth hormone. The downstream effects and safety implications are quite different.
The Most Common Peptides and What They Do
Holtorf runs through the major categories. Growth hormone secretagogues like CJC-1295, Ipamorelin, and Tesamorelin stimulate your pituitary to release growth hormone in a pulsatile pattern that mimics natural secretion. This matters because exogenous growth hormone (injecting HGH directly) produces a flat, constant level that can have more side effects. The pulsatile release from secretagogues is considered safer and more physiologically appropriate.
Healing peptides are the next category. BPC-157, originally derived from a protein found in gastric juice, has shown remarkable tissue repair properties in animal studies. It accelerates healing of tendons, ligaments, muscles, gut lining, and even nerve tissue. TB-500 (Thymosin Beta 4) works through a different mechanism, promoting cell migration and reducing inflammation at injury sites. Many practitioners stack BPC-157 and TB-500 together for synergistic healing effects.
Immune-modulating peptides include Thymosin Alpha 1, which enhances immune function by stimulating T-cell production and maturation. It has been used clinically in several countries for hepatitis B and C treatment and as an adjunct in cancer immunotherapy. LL-37 is an antimicrobial peptide that your body produces naturally as part of the innate immune response. Synthetic versions are being explored for chronic infections and biofilm disruption.
Then there are the newer entries. PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women. Selank and Semax are nootropic peptides developed in Russia that have anxiolytic and cognitive-enhancing properties. Epithalon is a telomerase-activating peptide that some longevity researchers are excited about, though human data is still limited.
Safety Concerns Holtorf Addresses Honestly
To his credit, Holtorf does not pretend peptides are risk-free. He identifies several legitimate concerns. First, sourcing. The peptide market is largely unregulated for research-use products. Quality varies dramatically between suppliers. Contamination, incorrect dosing, and outright counterfeits are real problems. He recommends using peptides only from compounding pharmacies or highly reputable research suppliers that provide third-party testing certificates.
Second, there is the regulatory reality. The FDA has been tightening restrictions on compounded peptides. Several popular peptides, including some forms of BPC-157 and CJC-1295 without DAC, have been placed on the FDA bulk substance list, meaning compounding pharmacies can no longer legally produce them (as of late 2023 and into 2024). This has pushed some users toward gray-market research suppliers, which carries its own risks.
Third, the evidence base is uneven. BPC-157 has hundreds of animal studies but very few human trials. TB-500 is in a similar position. Growth hormone secretagogues have more human data, but long-term safety studies spanning decades simply do not exist. Holtorf is upfront about this, saying that the clinical results he has seen in practice are strongly positive but acknowledging that the formal evidence lags behind clinical experience.
He also flags drug interactions. Peptides that affect growth hormone levels should be used cautiously in anyone with active cancer or a history of certain cancers, since growth hormone can promote cell proliferation. Immune-modulating peptides can theoretically worsen autoimmune conditions. And stacking multiple peptides simultaneously increases the complexity of predicting interactions.
Getting Started: A Reasonable Approach
Holtorf outlines what he considers a sensible entry point for someone interested in peptide therapy. His recommendation is to start with one peptide targeting your primary concern, whether that is recovery from an injury, improving sleep and body composition, or addressing immune function. Do not try to stack four or five peptides at once when you are new to this. You will not know what is doing what, and if you have a side effect, you will not know what caused it.
For body composition and anti-aging, a CJC-1295/Ipamorelin combination is his typical starting recommendation. It improves sleep quality (growth hormone is released primarily during deep sleep), supports fat loss, and may improve recovery from exercise. The standard dosing is subcutaneous injection before bed, usually five days on and two days off, though protocols vary between practitioners.
For injury recovery, BPC-157 is his go-to, either alone or combined with TB-500. He recommends subcutaneous injection near the injury site when possible, as local administration may concentrate the peptide where it is needed most. Typical cycles run 4-8 weeks.
For immune support, Thymosin Alpha 1 taken two to three times per week is his standard protocol. He uses this frequently in patients with chronic infections, post-viral fatigue, or immune suppression.
What to Discuss with Your Provider
If peptide therapy interests you, the first step is finding a provider who actually understands this space. Most conventional physicians have zero training in peptide therapy. Functional medicine doctors, integrative medicine specialists, and anti-aging clinicians are more likely to have experience. Ask potential providers how many patients they have treated with peptides, what outcomes they have seen, and what monitoring they perform.
Before starting, you should have baseline labs drawn. At minimum: IGF-1 (to track growth hormone effects), a complete metabolic panel, CBC, inflammatory markers (CRP, ESR), thyroid panel, and sex hormones. These give your provider a baseline to compare against after 8-12 weeks of therapy.
Ask about the specific source of the peptides being prescribed. Are they coming from a licensed compounding pharmacy? Is there a certificate of analysis? What is the purity level? These questions are not paranoid. They are basic due diligence in a market with real quality control problems.
Discuss the expected timeline. Most peptide effects take 4-8 weeks to become noticeable, with full benefits appearing over 3-6 months. If someone promises overnight results, that is a warning sign. And have a clear plan for when to stop. Not all peptides are meant to be used indefinitely. Cycling protocols, where you use a peptide for a defined period then take a break, are standard practice for many peptide therapies.
Dr. Holtorf provides a balanced, clinician-perspective introduction to a field that badly needs it. Peptides are not magic, but they are not snake oil either. They are a growing category of therapeutic tools with real biological mechanisms and genuine clinical potential, paired with the usual caveats about needing more and better human research.